The unmet clinical need
Despite decades of advances in cancer care, most cancers are still detected too late, often only after symptoms appear and through invasive, costly, and inefficient clinical pathways. As global cancer incidence continues to rise, healthcare systems face mounting clinical and economic pressure.
Today's standard of care relies heavily on the visual examination of tissue by pathologists using microscopy. While this approach has saved countless lives, it is fundamentally limited by human interpretation.
Subtle molecular changes that precede visible disease can remain undetected, accuracy can vary between observers, and obtaining definitive results requires invasive biopsies, labour intensive workflows, and days or weeks of processing. For patients, this often means prolonged uncertainty at one of the most critical moments in their care.
The next generation of oncology requires precision guidance that goes beyond what the human eye can see. By measuring objective biological signatures at the molecular level, precision technologies can enable earlier, more accurate detection, reduce unnecessary procedures, accelerate clinical decision making, lower healthcare costs, and ultimately improve survival and quality of life.
